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Abstract This 10-week study assessed the efficacy of
atomoxetine in combination with psychoeducation com-
pared to placebo and psychoeducation in the improvement
of Quality of Life in Swedish stimulant-naive children and
adolescents with attention deficit/hyperactivity disorder. A
total of 99 patients were treated with atomoxetine
(49 patients) or placebo (50 patients) for 10 weeks and
assessed regarding broader areas of functioning using the
Quality of Life measures Child Health and Illness Profile-
Child Edition (CHIP-CE), Family Strain Index [FSI;
equivalent to the Family Burden of Illness Module used in
the study], Appraisal of Stress in Child-Rearing (ASCR),
Five to fifteen (FTF), ‘‘I think I am’’ (‘‘Jag tycker jag a¨r’’),
and Children’s Depression Rating Scale-Revised (CDRS-R)
before and after the active treatment phase. Simultaneously,
the patients’ parents participated in a 4-session psychoedu-
cation program. A statistically significant difference in favor
of atomoxetine was seen in the improvement from baseline
to study endpoint for the CHIP-CE domains ‘‘Achievement’’
and ‘‘Risk avoidance’’, for the FSI total score, for the ASCR
section (I) domain ‘‘Child as a burden’’, for all FTF domains
except for ‘‘Language and Speech’’, and for the CDRS-R
total score. No difference between treatment groups was
observed in the patient-assessed evaluation of self-esteem
using the ‘‘I think I am’’ scale. Atomoxetine combined with
psychoeducation had a positive effect on various everyday
coping abilities of the patients as well as their families
during 10 weeks of treatment, whereas the patients’ self-
image and the parents’ image of the climate in the family
were not significantly improved.
Keywords ADHD  Atomoxetine  Quality of life 
CHIP-CE  Broader efficacy
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Introduction
Attention deficit/hyperactivity disorder (ADHD) is a com-
mon disorder in children and adolescents, with a prevalence
of 3–8% [2, 34]. The core symptoms of the disorder are age-
inadequate difficulties in sustaining attention and/or hyper-
activity/impulsivity, leading to functional impairments
within at least two life domains, e.g., in school, at work, at
home, etc. [2]. Current treatments of the disorder include
pharmacotherapy, preferably in combination with behav-
ioral and psychosocial interventions in order to enhance the
patients’ and parents’ capability to cope with the symptoms
and behavioral problems caused by ADHD, and to adapt the
environment to the child’s specific difficulties [5].
The efficacy of stimulants and atomoxetine, a non-
stimulant first licensed in the US in 2002, has been well
documented in clinical trials [3, 6]. During the recent years,
an increasing amount of research has investigated the
health-related quality of life (HRQL) and the functional
impairments of the daily life of patients with ADHD and
their parents, rather than the core symptoms of the disorder,
i.e., their ‘‘broader areas of functioning’’. However, such
measures are still considered as not thoroughly investigated
because of too infrequent applications or with too little
statistical power [7, 9].
Previous research has indicated that ADHD is associated
with a range of deficits in various areas of functioning such as
low self-esteem, emotional liability, academic under-
achievement, disturbed peer relations, and family interaction
[4, 22, 26]. The impairment of HRQL in children with
ADHD has been compared with the impairment in children
with somatic illness. For example, Escobar and coworkers
[15] compared HRQL, as measured by the Child Health
Questionnaire (CHQ-PF50) [20, 21], a generic, standardized
measure covering four ‘‘physical’’ and seven ‘‘psychoso-
cial’’ domains, in children with asthma, ADHD, and in
healthy controls. The results show that children with ADHD
were more severely impaired in their psychosocial and
physical functioning than healthy children, but also that this
impairment was even greater than in children with asthma,
mainly in areas related to psychosocial functioning.
During the development of atomoxetine, the CHQ was
used in several clinical trials in order to investigate the effect
of the treatment on HRQL, beyond the effect on core ADHD
symptoms. Perwien [29] summarized the results from three
placebo-controlled atomoxetine studies with a duration of 7–
8 weeks [23, 24, 41] including 403 patients on atomoxetine
and 181 on placebo. Atomoxetine-treated patients improved
on all seven psychosocial outcomes (self-esteem, behavior,
family activity, mental health, parent impact emotion, parent
impact time, and role function), while no aggravations, or
differences versus placebo were seen on the physical func-
tioning domains. In an open-label long-term study, 912
patients started treatment on atomoxetine, and patients who
continued the study were evaluated according to CHQ after
an ‘‘acute’’ phase of 10 weeks, and at 6 and 24 months [30].
Similar improvements as reported above were seen already
at 10 weeks in all psychosocial domains for those patients
who completed the full trial. Taken together, these results
suggest that improvements in HRQL as measured by the
CHQ, which are associated with atomoxetine treatment,
occur within a relatively short time frame.
Another generic measure of HRQL in children and ado-
lescents is the Child Health and Illness Profile-Child Edition
(CHIP-CE) [36, 37]. The CHIP-CE was used in a large
European prospective observational study on children and
adolescents with ADHD, the Attention Deficit/Hyperactiv-
ity Disorder Observational Research in Europe (ADORE)
study [33], which assessed the primary objective to describe
treatment regimens and HRQL during a 2-year period. The
CHIP-CE consists of five domains and a total score, and
similar to the CHQ, norms exist [37]. In the ADORE patient
sample, the mean baseline scores of the Achievement and
Risk avoidance domains were particularly deviant, indicat-
ing severe problems with school performance, peer relations,
and risk taking behavior [36]. In the UK ‘‘Sunbeam’’ study
[32] the CHIP-CE total score was used as the primary out-
come measure in a randomized open-label 10-week com-
parison of the HRQL of approximately 200 children and
adolescents treated with either atomoxetine or with ‘‘stan-
dard current therapy’’ (SCT). In the latter study arm, treat-
ments were given at the physician’s discretion, and more
than 80% of patients in that arm received stimulants, with or
without behavioral counseling. Similar to the ADORE, in
Sunbeam the CHIP-CE Achievement and Risk avoidance
domains were the most deviant domains at baseline. An
improvement for both treatment arms was seen for all CHIP-
CE domains including the total score, with a statistically
significantly greater improvement in atomoxetine-treated
patients in the primary measure, the CHIP-CE total score,
and in the five domain scores.
The present study was designed to investigate the changes
in HRQL as measured by the CHIP-CE during treatment
with atomoxetine and (parental) psychoeducation, compared
to placebo and psychoeducation, in stimulant-naive children
and adolescents with ADHD. The parental educational
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program itself, the efficacy of treatments on core ADHD
symptoms, and safety outcomes are presented in detail in a
separate paper [39]. As described above, in previous trials
with CHIP-CE as a measure of HRQL in ADHD, the two
domains of Achievement and Risk avoidance were most
deviant at baseline and changed most after treatment.
Therefore, the CHIP-CE Achievement domain was chosen
as primary outcome measure for the present study. Treat-
ment effects on health care resource utilization were also
measured and results are reported elsewhere [25].
Patients and methods
Study design, study population, and study treatments of this
multi-center, randomized, double-blind, placebo-con-
trolled, phase 3b study (B4Z-SO-LY15) are described in
detail elsewhere [39]. The study design and efficacy on
core ADHD symptoms and safety results are briefly sum-
marized below.
Patients were recruited consecutively from the clinics’
waiting lists; no site advertised for participants. Patients
had to be stimulant-naive and due to the relatively slow
onset of action for atomoxetine, and the 50% chance of
being randomized to placebo, not clinically assessed as
being in need of immediate symptom relief. Important
exclusion criteria included general impairment of intelli-
gence, serious medical illness, a history of psychosis or
bipolar disorder, alcohol or drug abuse within the previous
3 months, and ongoing use of psychoactive medication
other than the study drug. Patients who required immediate
pharmacotherapy or structured psychotherapy were also
excluded. Of the 102 patients screened, 99 met the entry
criteria and participated in the study.
After screening (Visit 1), eligible patients were random-
ized in a 1:1 ratio to a 10-week double-blind treatment with
either atomoxetine (n = 49) or placebo (n = 50). Ato-
moxetine dosage was according to the EU label, i.e., 0.5 mg/
kg during the first week of treatment, thereafter 1.2 mg/kg.
In parallel, the parents of the patients in both treatment
groups participated in a 4-session psychoeducational
training. The program was developed by a professional
educational manager especially for the conditions associ-
ated with this clinical study. The content of the program
contained core elements from more comprehensive behav-
ioral treatment programs like parental management training
(PMT), developed by Patterson and coworkers, e.g., [28]
and the community parent education program (COPE),
developed by Cunningham and coworkers, e.g., [10–12]. It
consisted of four 3-h parental group sessions and was led by
1 or 2 group leaders at each site. Since the participating
clinics had various experiences of psychoeducative meth-
ods, it was not considered feasible to include more than four
3-h ‘‘basic’’ sessions during the 10 weeks double-blind
study period II. The group leaders were trained by the
educational manager, and were provided with presentation
slides and a written material aiming to increase the parents’
knowledge of ADHD as a disorder, different kind of treat-
ments, the disorder’s psychological and behavioral conse-
quences for the child and its family, and how to cope better
with these consequences. Both parents/caregivers were
invited and encouraged to participate, and did so in the
majority of cases. Since the program was not monitored by
the sponsor, it is not possible to present any absolute
numbers of attendance. The psychoeducation is more
thoroughly described in a previous paper [39].
Atomoxetine or placebo was dispensed at 6 visits (Visits
2–7) during the active treatment phase. After completion of
the double-blind phase, all patients were offered the option of
entering an open-label extension, during which all patients
received atomoxetine until it became commercially avail-
able in Sweden, but for no longer than 9 months. This paper
reports results from the double-blind phase of the study.
Written informed consent was obtained before any
study-related procedures. The study was conducted
according to good clinical practice guidelines.
Summary of demographics, baseline characteristics,
efficacy and safety parameters
Demographics and baseline characteristics were similar in
both treatment groups. The study population was predom-
inantly male (80.8%) and diagnosed with the combined
ADHD subtype (77.8%). Baseline total ADHD-RS scores
expressed as mean (SD) were 38.9 (7.7) and 39.5 (6.7) for
atomoxetine and placebo-treated patients, respectively. The
ADHD diagnosis as well as comorbid conditions were
confirmed with the Kiddie Schedule for Affective Disor-
ders and Schizophrenia for School-Age Children-Present
and Lifetime Version (K-SADS-PL) [19]. The most fre-
quent comorbid disorder was oppositional/defiant disorder
(20.2%), followed by tics (14.1%) and major depressive
disorder (5.1%: 2 patients on atomoxetine, 3 on placebo).
No patient fulfilled criteria for conduct disorder. The least
square mean (lsmean) change from baseline to endpoint in
total ADHD-RS score was -19.0 for atomoxetine patients
and -6.3 for placebo patients, resulting in an effect size of
1.3 at endpoint. Treatment response, as measured by a
reduction in ADHD-RS score of C25% (or C40%) was
achieved in 71.4% (or 63.3%, respectively), of atomoxetine
patients and 28.6% (or 14.3%) of placebo patients. The
lsmean change from baseline to endpoint in CGI-Severity
was -1.8 in the atomoxetine group compared with -0.3 in
the placebo group. The difference between treatments in
CGI-Improvement at endpoint was -1.4 points in favor of
atomoxetine. No serious adverse events (SAEs) occurred.
Eur Child Adolesc Psychiatry (2009) 18:725–735 727
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The safety profile was in line with the label, with headache,
fatigue, and gastrointestinal symptoms (abdominal pain
upper and anorexia/decreased appetite) most commonly
reported. No patient discontinued during the double-blind
study period II [39].
Assessments
The primary efficacy variable of this study was the domain
‘‘Achievement’’ of the Child Health and Illness Profile-Child
Edition-Parent Form (CHIP-CE-Parent form) [37], a 76-item
generic HRQL questionnaire covering a total of 5 domains
(‘‘Satisfaction’’, ‘‘Comfort’’, ‘‘Risk avoidance’’, ‘‘Resil-
ience’’, and ‘‘Achievement’’). The CHIP-CE scores are
standardized to t scores, i.e., to a mean ± SD of 50 ± 10,
based on the norms of a sample of 1,049 US school children,
with higher scores indicating better health. Scores of the
other CHIP-CE-Parent form domains, and the CHIP-CE total
score (the mean of the separate domains) [35], were assessed
as secondary efficacy measures. Based on a factor analysis
from the ADORE study [33], Riley and her group [36]
reported that the ‘‘Achievement’’ domain’s subdomains
‘‘Peer relations’’ and ‘‘Academic performance’’ appeared as
separate factors in an ADHD sample, so that the CHIP-CE
now comprises six domains instead of the initial five. Thus,
results from the aforementioned subdomains are also pre-
sented. An improvement is indicated by an increase in scores.
Further secondary outcomes were the mean changes in
several other HRQL assessments: the Family Strain Index
(FSI), a newly developed 6-item questionnaire to determine
the effect of a child’s ADHD on the functioning of their
immediate family, was investigated for the 2 domains
‘‘Emotional’’ and ‘‘Restriction’’ in the 4 settings ‘‘Global’’,
‘‘Home’’, ‘‘Outside home’’, and ‘‘Family’’. A high FSI
score indicates a high family strain. The FSI was recently
validated by Riley and her group [38] based on data from
the ADORE study [33], in which 1,477 parents of patients
aged 6–18 years completed the form. A factor analysis of
the data from this study [38] showed that the FSI taps into
an overall experience of worry and interruptions of activ-
ities in families of children with ADHD, and a single factor
(e.g., the total score) was identified with excellent internal
consistency and almost no ceiling or floor effects were
observed for this special population. The FSI was also used
in the Sunbeam study [32]; however, the instrument was
named the Family Burden of Illness Module (FBIM),
likewise in the present study.
Appraisal of Stress in Child-Rearing (ASCR) was origi-
nally constructed and evaluated in Holland (Nijmegen Child-
Rearing Situation Questionnaire; NCSQ). The NCSQ con-
siders measures on child-rearing in four different sections; in
the present study only the first two were used: (1) subjective
parenting stress; (2) global appraisal of the child-rearing
situation. Section (1) consists of 46 items, covering 8 dif-
ferent concepts of stress, such as strain, burden, problems,
etc. It was translated to Swedish and validated in a sample of
parents to children with and without ADHD. The Swedish
version has appropriate psychometric properties [18]. The
NCSQ was used as a measure of changes in parents’ attitudes
towards their children during the study.
The ‘‘Five to fifteen’’ (FTF) questionnaire [17] was
developed in Scandinavia and consists of 181 parent asses-
sed items covering the 8 developmental/neuropsychiatric
domains ‘‘Motor control’’, ‘‘Executive function’’, ‘‘Percep-
tion’’, ‘‘Memory’’, ‘‘Language and speech’’, ‘‘Learning’’,
‘‘Social competence’’, and ‘‘Emotional/behavioral prob-
lems’’. They indicate their agreement/disagreement on each
item, containing a short, specific statement, e.g., ‘‘Interrupts
or intrudes on others’’ or ‘‘Loses temper’’ with 0 = ‘‘does
not apply’’, 1 = ‘‘applies sometimes or to some extent’’, and
2 = ‘‘definitely applies’’. Norms exist for Scandinavian
children and adolescents between 5 and 15 years, and the
FTF has also been validated in children with ADHD and
other neuropsychiatric disorders [1].
The’’I think I am’’ (‘‘Jag tycker jag a¨r’’) scale [27] was
developed in Sweden. It assesses various aspects of the
patient’s self-esteem, and is scored by the children them-
selves. It was chosen for this study due to existing Swedish
norms (z-scores; with a mean of 5, and SD of 2).
Depending on the children’s age two different scales were
used, the L-scale (‘‘Low stage’’) with 32 questions (scored
-1 or ?1) for children aged 7–10 years, summarized to a
total L-score, and the MH-scale (‘‘Middle-high stage’’)
with 72 questions (scored -2 to ?2) in the domains
‘‘Physical abilities’’, ‘‘Performance’’, ‘‘Psychic Well-
Being’’, ‘‘Family Relations’’, and ‘‘Relations to Peers’’, and
a total MH-score for children aged 11–16 years. For both
scales, a high score indicates a high perceived competence.
The Children’s Depression Rating Scale-Revised
(CDRS-R) [31], a 17-item scale to measure presence and
severity of depression scored by the clinician, is modeled
after the Hamilton Depression Rating Scale for adults, but
additionally includes questions about school. The total
score ranges from 17 to 113, with high scores indicating a
high degree of depression.
QoL assessments were performed at baseline (Visit 2 for
all QoL measures except for CDRS-R and FTF, for which
baseline assessments were performed at Visit 1) and at the
study endpoint (Visit 7, week 10).
Sample size determination
Although the CHIP-CE had been used in completed trials in
somatically ill children, no data were published on its use in
psychiatric samples at the time of initiation of the present
study. The CHIP-CE is standardized on an US sample to t
728 Eur Child Adolesc Psychiatry (2009) 18:725–735
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scores, i.e., to mean ± SD of 50 ± 10. A change of
approximately 0.5SD, i.e., *5 points, is considered as a
clinically relevant change (Riley A, personal communica-
tion). Approximately 100 patients were planned to be ran-
domized to atomoxetine or placebo treatment in a 1:1 ratio.
The sample size was calculated for 80% or more power to
detect a difference of C6.0 units on the standardized CHIP-
CE achievement domain mean score between treatment
groups with respect to the change in score from baseline to
that after 10 weeks of treatment. A 5% significance level
was used, and calculations were done with the Students t test.
The discontinuation rate was estimated to be 10%.
Statistics
The primary efficacy analysis was the mean score of the
CHIP-CE ‘‘Achievement’’ domain. The last observation
carried forward (LOCF) change from baseline to endpoint
was analyzed by an analysis of covariance (ANCOVA)
model including terms for baseline score, treatment, site,
visit, and treatment-by-visit interaction. Baseline was
defined as scores obtained at Visit 2, before randomization.
Furthermore, the analysis included the baseline CDRS-R
score as a covariate in order to adjust for potential imbal-
ances in this scale at baseline that may affect HRQL.
Similar analyses were performed on the 4 other domains of
the CHIP-CE (‘‘Satisfaction’’, ‘‘Comfort’’, ‘‘Resilience’’,
and ‘‘Risk avoidance’’), the total scores of the CHIP-CE
and the subdomains. The other HRQL questionnaires were
analyzed using an ANCOVA model applied on the LOCF
change from baseline to endpoint including terms for site,
treatment, and baseline score. All analyses were conducted
using PROC MIXED of the SAS software. Estimates for
the change within treatment group (incl. standard error) and
for the difference between treatment groups plus corre-
sponding 95% confidence interval (CI) and P value, as well
as descriptive statistics (N, mean, standard deviation,
median and range) were presented.
All statistical tests were 2-sided with a nominal signif-
icance level of 5%. Analysis of the CHIP-CE-Parent form
domains included adjustments of the significance levels for
multiplicity.
Results
HRQL: efficacy results
At baseline, there were no relevant differences for the
CHIP-CE total score or any of its domains between the two
treatment groups (Table 1). At study endpoint, the mean
change from baseline for the ‘‘Achievement’’ domain score
was more than twice as high in the atomoxetine group (6.9)
than in the placebo group (3.0), and this difference was
statistically significant (P = 0.010). Similarly, the change
in the ‘‘Risk avoidance’’ domain was statistically signifi-
cantly higher (P = 0.041) in the atomoxetine group (7.1)
than in the placebo group (3.9). For all other changes in
domains and the total CHIP-CE score differences between
the two treatment groups were not statistically significant.
The impact of comorbid conditions, particularly ODD,
on the change in CHIP-CE domain scores is of obvious
interest for physicians treating patients with ADHD. Due to
the relatively small sample size (N = 99), and the fact that
only 20.2% of the patients (n = 19) fulfilled criteria for
ODD, the statistical power to show a possible interaction of
such comorbidity is insufficient in this pre-planned sec-
ondary analysis. Yet, the numerical improvement in all five
Table 1 CHIP-CE domain scores and total score
CHIP-CE domain Baseline score [mean (SD)] Endpoint score
LS mean change from baseline (SE) Difference in LS means
Subdomain Atomoxetine
(N = 49)
Placebo
(N = 50)
Atomoxetine
(N = 49)
Placebo
(N = 50)
Estimate
(95% CI)
P value
Total score 28.3 (10.3) 30.5 (10.8) 6.6 (1.2) 5.2 (1.2) 1.5 (-1.8; 4.8) 0.381
Achievement 29.2 (9.9) 29.8 (8.9) 6.9 (1.0) 3.0 (1.1) 3.9 (0.9; 6.8) 0.010
Peer relations 34.6 (13.5) 35.8 (13.5) 4.5 (0.9) 2.2 (0.9) 2.2 (-0.3; 4.8) 0.087
Academic performance 32.0 (10.0) 31.3 (8.0) 6.7 (1.2) 2.4 (1.3) 4.2 (0.8; 7.6) 0.015
Satisfaction 31.8 (13.4) 34.0 (13.7) 3.4 (1.7) 4.8 (1.7) -1.4 (-6.1; 3.2) 0.540
Comfort 44.1 (9.1) 44.1 (8.7) 3.3 (1.1) 4.7 (1.2) -1.4 (-4.5; 1.8) 0.396
Resilience 35.8 (11.4) 39.5 (12.2) 3.0 (1.1) 2.8 (1.1) 0.2 (-3.0; 3.4) 0.904
Risk avoidance 32.7 (12.6) 34.9 (11.9) 7.1 (1.1) 3.9 (1.1) 3.2 (0.1; 6.3) 0.041
Baseline and change from baseline to endpoint
CHIP-CE Child health and illness profile-child edition, N maximum number of patients, SD standard deviation, LS least square, SE standard
error, CI confidence interval
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domains was similar or greater for patients without ODD
(range 0–2.1). For Achievement, patients on atomoxetine
without/with ODD improved equally [7.4 (SD = 8.0) vs.
7.4 points (SD = 11.5), respectively]. For Risk avoidance,
corresponding values were 7.5 points (SD = 9.3) versus
6.7 points (SD = 9.1), respectively.
The FSI total score as well as the scores for its domains
‘‘Emotional’’ and ‘‘Restriction’’ decreased from baseline to
study endpoint with both treatments, with higher decreases
in atomoxetine than in placebo patients (Table 2). The
between group difference for the total FSI score was sta-
tistically significant (change of -2.2 in the atomoxetine
group and -0.5 in the placebo group; P = 0.046).
There were only minor changes from baseline to study
endpoint in the section (I) domains of the ASCR (Table 3).
The 2 treatment groups did not differ significantly with the
only exception of the domain ‘‘Child as a burden’’, for
which the mean change was -0.18 in the atomoxetine
group and 0.05 in the placebo group (P = 0.007).
For all FTF domain sores, there was a larger decrease
(i.e., improvement) in the atomoxetine group compared to
the placebo group (Table 4). Between-treatment differ-
ences were statistically significant for all domains (P val-
ues between \0.001 and 0.033) with the exception of the
‘‘Language and Speech’’ domain (P = 0.115).
There were no statistically significant differences between
atomoxetine and placebo in the ‘‘I think I am’’ total scores or
the domains of the ‘‘I think I am’’ MH-scale (Table 5).
Results showed no consistent trend for either treatment
group as both increases (i.e., improvements) and decreases
occurred depending on the score and/or the treatment group.
The CDRS-R total score decreased from baseline to study
endpoint in the atomoxetine group (mean change of -3.4),
whereas it remained almost unchanged in the placebo group
(mean change of -0.1). The corresponding estimate for the
difference between the two treatment groups of -3.3 was
statistically significant (P = 0.033; 95% CI: [-6.4; -0.3]).
Since only two patients in the atomoxetine group and three
Table 2 FSI total score and domain scores
FSI domain Baseline score [mean (SD)] Endpoint score
LS mean change from baseline (SE) Difference in LS means
Atomoxetine
(N = 49)
Placebo
(N = 50)
Atomoxetine
(N = 49)
Placebo
(N = 50)
Estimate
(95% CI)
P value
Total score 9.8 (4.7) 8.8 (4.6) -2.2 (0.6) -0.5 (0.6) -1.8 (–3.5; 0.0) 0.046
Emotional 3.4 (1.7) 3.3 (1.7) -0.8 (0.2) -0.3 (0.2) -0.5 (-1.1; 0.1) 0.102
Restriction 6.5 (3.2) 5.5 (3.3) -1.4 (0.5) -0.1 (0.5) -1.2 (-2.5; 0.0) 0.056
Baseline and change from baseline to endpoint
FSI family strain index, N maximum number of patients, SD standard deviation, LS least square, SE standard error, CI confidence interval
Table 3 ASCR section (I) and section B scores
ASCR score Baseline score [mean (SD)] Endpoint score
LS mean change from baseline (SE) Difference in LS means
Atomoxetine
(N = 49)
Placebo
(N = 50)
Atomoxetine
(N = 49)
Placebo
(N = 50)
Estimate
(95% CI)
P value
Section (I)
Acceptance 2.91 (0.36) 2.82 (0.50) 0.01 (0.05) 0.02 (0.05) -0.01 (-0.15; 0.13) 0.888
Coping 2.76 (0.28) 2.83 (0.31) 0.07 (0.04) -0.04 (0.04) 0.10 (-0.01; 0.22) 0.069
Experiencing problems 3.20 (0.43) 3.11 (0.37) 0.01 (0.05) 0.03 (0.05) -0.01 (-0.15; 0.13) 0.871
Need for a change 3.35 (0.59) 3.37 (0.45) 0.12 (0.06) 0.07 (0.06) -0.05 (-0.11; 0.21) 0.549
Child as a burden 3.29 (0.39) 3.15 (0.44) -0.18 (0.06) 0.05 (0.06) -0.24 (-0.41; -0.06) 0.007
Managing on ones own 2.92 (0.42) 2.88 (0.38) 0.09 (0.05) 0.08 (0.05) 0.02 (-0.12; 0.16) 0.797
Pleasure 1.76 (0.58) 1.69 (0.57) -0.19 (0.07) -0.13 (0.07) -0.06 (-0.25; 0.12) 0.496
Relation 3.26 (0.55) 3.33 (0.63) 0.12 (0.07) 0.13 (0.07) -0.01 (-0.21; 0.18) 0.889
Section B 4.53 (1.43) 4.52 (1.38) -0.57 (0.15) -0.36 (0.15) -0.21 (-0.63; 0.21) 0.325
Baseline and change from baseline to endpoint
ASCR appraisal of stress in child-rearing, N maximum number of patients, SD standard deviation, LS least square, SE standard error, CI
confidence interval
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patients in the placebo group fulfilled criteria for major
depressive disorder [39] (and the mean CDRS-R scores at
baseline were as low as*25; possible range 17–113), we do
not consider this statistically significant difference to reflect
proof of an antidepressant effect of atomoxetine, but rather
an effect of overlapping items in the CDRS-R and ADHD-
RS scales, e.g., ‘‘work and activities’’.
Discussion
The baseline scores of mainly the CHIP-CE domains
Achievement and Risk avoidance in the present study of
Swedish treatment-naive children and adolescents with
ADHD confirm the picture seen in previous European
studies [32, 33]: the HRQL of these children is particularly
Table 4 FTF domain scores
FTF domain Baseline score [mean (SD)] Endpoint score
LS mean change from baseline (SE) Difference in LS means
Atomoxetine
(N = 49)
Placebo
(N = 50)
Atomoxetine
(N = 49)
Placebo
(N = 50)
Estimate
(95% CI)
P value
Motor control 0.58 (0.39) 0.63 (0.45) -0.18 (0.03 -0.06 (0.03) -0.12 (-0.21; -0.03) 0.012
Executive function 1.42 (0.33) 1.38 (0.36) -0.39 (0.05) -0.08 (0.05) -0.31 (-0.46; -0.17) \0.001
Perception 0.70 (0.38) 0.54 (0.37) -0.20 (0.04) -0.03 (0.04) -0.17 (-0.29; 0.06) 0.004
Memory 0.85 (0.47) 0.70 (0.35) -0.11 (0.04) 0.02 (0.04) -0.13 (-0.26; -0.01) 0.033
Language and speech 0.60 (0.43) 0.43 (0.30) -0.12 (0.03) -0.06 (0.03) -0.07 (-0.15; 0.02) 0.115
Learning 1.15 (0.44) 1.13 (0.37) -0.22 (0.04) -0.07 (0.04) -0.15 (-0.27; -0.04) 0.008
Social competence 0.76 (0.43) 0.61 (0.44) -0.20 (0.04) -0.06 (0.04) -0.14 (-0.25; -0.04) 0.009
Emotional/behavioral 0.60 (0.35) 0.55 (0.35) -0.18 (0.03) -0.08 (0.03) -0.10 (-0.19; -0.01) 0.031
Baseline and change from baseline to endpoint
N maximum number of patients, SD standard deviation, LS least square, SE standard error, CI confidence interval
Table 5 ‘‘I think I am’’ scores
‘‘I think I am’’ score Baseline score (n) Endpoint score
Mean (SD) LS mean change from baseline (SE) Difference in LS means
Atomoxetine
(N = 49)
Placebo
(N = 50)
Atomoxetine
(N = 49)
Placebo
(N = 50)
Estimate
(95% CI)
P value
Total score 39 34 0.28 (0.25) 0.13 (0.26) 0.15 (-0.55; 0.85) 0.671
4.97 (1.63) 4.85 (1.74)
L-scale total 12 13 0.63 (0.58) 0.01 (0.57) 0.62 (-1.05; 2.29) 0.438
5.33 (1.87) 5.31 (1.97)
MH-scale total 27 21 0.10 (0.23) 0.31 (0.27) -0.21 (-0.92; 0.50) 0.553
4.81 (1.52) 4.57 (1.57)
MH-scale domains
Physical abilities 31 27 -0.51 (0.27) -0.52 (0.28) 0.02 (-0.75; 0.79) 0.960
5.42 (1.84) 5.67 (2.02)
Performance 29 26 0.32 (0.24) -0.22 (0.27) 0.53 (-0.19; 1.26) 0.147
4.66 (1.97) 5.46 (1.65)
Physical well-being 31 29 0.76 (0.24) 0.24 (0.25) 0.52) (-0.17; 1.20 0.137
3.77 (1.54) 3.59 (1.74)
Family relations 30 29 -0.29 (0.31) 0.08 (0.32) -0.37 (-1.25; 0.51) 0.398
4.53 (1.94) 4.52 (1.90)
Relation to peers 28 26 -0.14 (0.30) 0.10 (0.32) -0.24 (-1.12; 0.64) 0.590
5.54 (1.91) 4.77 (1.95)
Baseline and change from baseline to endpoint
L-scale children 7–10 years, MH-scale children 11–16 years, n number of evaluable patients, N maximum number of patients, SD standard
deviation, LS least square, SE standard error, CI confidence interval
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negatively affected within the areas of school performance,
peer relations, and risk taking behavior. Also CHIP-CE
Satisfaction and Resilience were impaired compared to
normal children. In this study, many of the patients’
broader areas of functioning, i.e., HRQL and functional
outcomes, improved significantly better under treatment
with atomoxetine and psychoeducation than under placebo
and psychoeducation. The mean change from baseline to
study endpoint in the primary efficacy variable, the CHIP-
CE ‘‘Achievement’’ domain, was 6.9 in the atomoxetine
group and 3.0 in the placebo group, which led to a statis-
tically significant difference between treatment groups
(P = 0.010). Additionally, the improvement in the ‘‘Risk
avoidance’’ domain of the CHIP-CE was also statistically
significantly larger for atomoxetine patients than for pla-
cebo patients. Thus, there were clear indications that
patients treated with atomoxetine performed better in
school compared to placebo-treated patients (P = 0.015),
their peer relationships improved (although not statistically
significant compared with placebo; P = 0.087), and their
risk taking behavior decreased. The FSI decreased signifi-
cantly more for atomoxetine-treated patients than for pla-
cebo, indicating less worry and interruptions of activities in
families of atomoxetine-treated patients. This finding is
consistent with the results measured by the ASCR, which
indicated a significant reduction of the perception of the
‘‘child as a burden’’, and a trend towards improvement in
‘‘family coping’’ in parents of atomoxetine-treated patients,
and with the statistically significant changes in favor of
atomoxetine treatment over placebo in seven of eight FTF
developmental/neuropsychiatric domains (Motor control,
Executive function, Perception, Memory, Learning, Social
competence, and Emotional behavior).
No statistically significant differences were seen in the
other CHIP-CE domains, Satisfaction, Resilience, and
Comfort, which all include subdomains related to bodily
functioning, i.e., areas usually not primarily affected in
patients with ADHD. Furthermore, the baseline score of the
domain Comfort was within the normal range (t score
*44), leaving very little space for change/differentiation
between treatment groups. In the UK ‘‘Sunbeam’’ study
[32], all five CHIP-CE domains and its total score managed
to differentiate between atomoxetine treatment and stan-
dard current therapy. This may be explained by several
differences between the two studies. In the UK study, all
patients were eligible for pharmacological treatment. As a
group, they were also more severely affected, with a
severity of illness as measured with ADHD-RS scores at
baseline of *45, compared to 39 in the present study. In
the present study, all patients were stimulant naive, and
patients requiring immediate therapy were excluded. These
baseline conditions of the UK study were also reflected in
lower baseline values for some of the CHIP-CE domains,
e.g., in t scores for Satisfaction and Risk avoidance as low
as *33–35, and *20, respectively. Finally, the fact that
Sunbeam was an open-label study might have introduced a
bias, which may have influenced the results.
Interestingly, the present results regarding the changes
in CHIP-CE domains are consistent with the results of
another placebo-controlled study, investigating HRQL in
Spanish children and adolescents with ADHD (14). Similar
to the present study, all patients were stimulant-naive, had
a similar baseline severity (ADHD-RS *39), and comor-
bidity (prevalence of ODD 25.5%). However, the statistical
power was higher (151 patients), but no psychoeducation
was given. In this Spanish study, only the CHIP-CE
domains Achievement and Risk Avoidance, as assessed by
parents improved significantly more in atomoxetine-treated
patients compared to patients treated with placebo.
The significant changes in 7 out of 8 FTF domains
indicate that atomoxetine does not only affect ADHD
symptoms positively, but also many other areas of
developmental/neuropsychiatric functioning. The domain
score for Executive functioning was the most deviant at
baseline. This is not surprising, since it consists of 27
variables, the main part of these being 2 subdomains
covering 9 items each (attention, and hyperactivity/
impulsiveness), directly modeled on the DSM-IV criteria
for ADHD. Two additional subdomains, Hypoactivity (4
variables) and Planning/organizing (3 variables), did also
improve significantly better for atomoxetine than for
placebo (post hoc analysis). The FTF domain Language
and speech was the only one that did not differ signifi-
cantly between the treatment arms, however, the mean
baseline score for this domain was the lowest, i.e., the less
deviant of the developmental areas of the entire study
sample at baseline. Interestingly, the validity of the FTF
baseline scores of the present study is supported by very
similar FTF profiles presented in 2 Scandinavian studies
in children and adolescents with a DSM-IV diagnosis of
ADHD [1, 8].
The statistically significant advantage in CHIP-CE
Achievement of *4 points for atomoxetine and psycho-
education versus placebo and psychoeducation was some-
what smaller than the predefined difference of 5 points that
the sample size calculation was based upon. We interpret
this difference nevertheless as clinically relevant, in par-
ticular when also considering the results of the changes in
other instruments of the present study. The very consistent
changes in core HRQL measures in ADHD-patients, such
as Achievement and Risk avoidance are in line with the
improvements in the 7 FTF domains, the reduced parental
experience of family strain (FSI), and child as a burden
(ASCR).
These changes are also consistent with the pronounced
decline in core ADHD symptoms in the atomoxetine group
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as compared to the placebo group. The possible influence
of the psychoeducational intervention on the high effect
size on the core ADHD symptoms of atomoxetine-treated
patients in the present study (effect size of 1.3) is discussed
in more detail by Svanborg and coworkers [39]. Since the
effect of atomoxetine and psychoeducation was unusually
high in the present study compared to other atomoxetine
studies without psychoeducation, concurrent with a similar
treatment response with placebo and psychoeducation as in
placebo arms of these studies, it was hypothesized that the
high effect size, at least partially, might be the result of an
interaction between atomoxetine and psychoeducation,
possibly in part supported by increased treatment compli-
ance. Similar factors may have contributed to the above
described effect on HRQL and functional measures.
However, other parent-rated functional areas related to
physical functioning failed to differ between treatment
groups, as did several measures of parent and patient
assessments of subjective well-being, self-esteem and the
emotional climate in the family. For both the ASCR and
the ‘‘I think I am’’, comparative data from other studies in
patient populations with ADHD is not available to provide
better understanding of this lack of differentiation. The ‘‘I
think I am’’ scale was chosen instead of Harter’s [16] more
known and internationally more frequently used instrument
(e.g., in the Sunbeam study) due to the existence of
Swedish norms for the ‘‘I think I am’’ scale. One possible
reason for the lack of differentiation in the scores of this
patient-assessed scale is the insufficient statistical power
due to the split of the data sets in 2 age groups and due to
missing data. The validity of self-assessments of ADHD
children and adolescents has also been questioned [13].
Also in the SUNBEAM study, where all 5 CHIP-CE
domains differentiated between the atomoxetine and SCT
groups, only one of the 6 domains of the Harter scale,
‘‘scholastic competence’’ succeeded to differentiate
between the groups. In the study by Escobar and coworkers
described above [14], additional to parental CHIP-CE rat-
ings also the child or adolescent version of the CHIP [37]
was assessed and compared with parents’ ratings. Inter-
estingly, all CHIP domains were rated within the normal
range by the patients. Baseline scores when assessed by a
child or adolescent were consequently higher than the
parents’ score. However, among the patient-assessed
domains, Achievement had the lowest baseline value
(m = 42.1–44,6) and improved significantly more for
atomoxetine-treated patients compared to patients treated
with placebo. In sum, this signifies a disagreement between
patients and parents reports of HRQL, but also that children
with ADHD may acknowledge problems with social and
academic functioning, which is a result in line with the
SUNBEAM findings. One other possibility is that the
treatment period of 10 weeks was not long enough to also
show improvements in areas of possibly more slowly
changing mind-sets such as subjective well-being, self-
esteem, and self-image of patients as well as of parents.
Further insight into this research question may be gained
when data from the open-label continuation phase of the
present study are analyzed.
At least two uncommon features of the present study
may limit the generalizability of the results: the concomi-
tant psychoeducation and the inclusion of only stimulant-
naive patients. Even if pharmacological treatment,
according to common treatment guidelines such as the
European Guidelines [3, 26] or the Strattera SPC [40]
should always be only one part of a comprehensive treat-
ment program, which also should include reinforcing psy-
chosocial interventions, it’s unclear to which degree such
interventions are implemented in ‘‘the real world’’. In the
present study, only four sessions of psychoeducation were
given. This is fewer compared to other, more comprehen-
sive educational programs, and may represent a weakness
of the study. Anyhow, we believe that the high effect size
on ADHD core symptoms in the present study was posi-
tively impacted by the psychoeducation (e.g., increased
compliance, and/or a positive interaction effect between
pharmacological and psychosocial treatments) and by
inclusion of fewer treatment resistant patients (with no or
few clear expectations of medication effects [39]) com-
pared to other studies. However, in spite of all patients
being stimulant naive, baseline severity in the present study
was similar to that of other placebo-controlled atomoxetine
trails. Due to the lack of a control group of patients
receiving atomoxetine but without parental education, the
impact of the psychoeducation on parents’ ratings of the
HRQL-related measures, i.e., on behaviors and functions
not always obviously associated with the neuropsychiatric
disorder, remains unclear.
The study was not designed to detect possible differing
treatment effects on HRQL for patients with or without
comorbidities like ODD. Thus, there is insufficient power
to detect such interactions. However, an analysis of these
interactions is currently planned for the combination of
several studies using similar HRQL scales. Furthermore,
analyses of long-term effects on the HRQL measures of the
present study are underway, and will also be published
separately.
Conclusions
Atomoxetine combined with psychoeducation had a posi-
tive effect on various everyday coping abilities of the
patients as well as their families during 10 weeks of
treatment, whereas the patients’ self-image and the parents’
image of the climate in the family were not shown to be
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significantly improved compared to placebo combined with
psychoeducation.
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